Maureen McArthur Hart

About Maureen Mcarthur Hart

Maureen McArthur Hart joins the RARE Daily Global Genes team covering public policy issues and advances in scientific research. She has a Ph.D. from George Washington University in science and technology public policy, an M.S. from Virginia Tech in science and technology studies, and a B.S. in biology from UCLA. Her career has included public affairs/public relations and clinical trials regulatory analysis at the University of Kentucky Medical Center and policy and research analysis at the Science and Technology Policy Institute in Washington, D.C.

She is dedicated to improving the scientific research and innovation process to make therapeutic development faster, more efficient, and more effective. She is also a cat-, dog-, and kid-person who enjoys the outdoors.

She can be reached at mhmcarthur@gmail.com or @mmhart.

 

About Maureen McArthur Hart

About Maureen Mcarthur Hart

Maureen McArthur Hart joins the RARE Daily Global Genes team covering public policy issues and advances in scientific research. She has a Ph.D. from George Washington University in science and technology public policy, an M.S. from Virginia Tech in science and technology studies, and a B.S. in biology from UCLA. Her career has included public affairs/public relations and clinical trials regulatory analysis at the University of Kentucky Medical Center and policy and research analysis at the Science and Technology Policy Institute in Washington, D.C.

She is dedicated to improving the scientific research and innovation process to make therapeutic development faster, more efficient, and more effective. She is also a cat-, dog-, and kid-person who enjoys the outdoors.

She can be reached at mhmcarthur@gmail.com or @mmhart.

 

Greater Patient Access to Fed-Funded Scientific Research? Coming in 2015
Rare disease patients, advocacy organizations, and researchers will soon have greater access to results from federally-funded scientific… Continue Reading
New Large-Scale Genetic Sequencing Effort to Identify Causes of Rare Developmental Disorders
A collaboration between the Wellcome Trust Sanger Institute, the UK Department of Health, and UK genetics services aims to identify genetic… Continue Reading
First Gene Therapy Drug Approved in Europe Set to Launch, Priced at U.S. $1.4 million
Glybera, the first gene therapy drug that has been approved by European regulators, is set to launch in Germany in early 2015 with a 1.1… Continue Reading
Legislation Introduced in House to Provide Incentives for Rare Disease Drug Development
On Nov. 20, 2014, Rep. Gus Bilirakis (R-FL) introduced the “Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2014”… Continue Reading
Could B-Corporations Be a New Investment Model for Non-Profits?
Maureen Mcarthur Hart Reports: The Cystic Fibrosis Foundation (CFF) announced last week that the organization has sold for $3.3 billion its… Continue Reading
be-a-guest-blogger

Follow us on Twitter